As mentioned in Rob Gregory’s excellent Christmas Chair’s bulletin (See HERE), the manufacturers of Lucozade have recently given notice of their intentions to reduce its glucose content. The timing coincides with national plans for a sugar tax and with plans for reformulation around implementation of the Childhood Obesity Plan. This will therefore require a different volume when Lucozade is used for oral glucose tolerance testing (OGTT). While OGTT is now used less frequently for formal diagnosis of Type 2 diabetes, it remains the NICE recommended test for diagnosis of gestational diabetes (NICE NG3) in those at risk, so I am concerned that all efforts are made to ensure units are made aware before the planned changes. We gather the changes are intended to take effect around May 2017.
